379 related articles for article (PubMed ID: 29442276)
1. Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization.
Kim JH; Sinn DH; Lee JH; Hyun D; Cho SK; Shin SW; Chang Y; Kim YJ; Yoon JH; Kang W; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Choi MS
Dig Dis Sci; 2018 Apr; 63(4):1062-1071. PubMed ID: 29442276
[TBL] [Abstract][Full Text] [Related]
2. Independent Analysis of Albumin-Bilirubin Grade in a 765-Patient Cohort Treated with Transarterial Locoregional Therapy for Hepatocellular Carcinoma.
Hickey R; Mouli S; Kulik L; Desai K; Thornburg B; Ganger D; Baker T; Abecassis M; Ralph Kallini J; Gabr A; Gates VL; Benson Iii AB; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2016 Jun; 27(6):795-802. PubMed ID: 27038686
[TBL] [Abstract][Full Text] [Related]
3. Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades Accurately Predict Overall Survival in High-Risk Patients Undergoing Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
Hansmann J; Evers MJ; Bui JT; Lokken RP; Lipnik AJ; Gaba RC; Ray CE
J Vasc Interv Radiol; 2017 Sep; 28(9):1224-1231.e2. PubMed ID: 28688815
[TBL] [Abstract][Full Text] [Related]
4. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
5. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
6. Liver Function Assessment Using Albumin-Bilirubin Grade for Patients with Very Early-Stage Hepatocellular Carcinoma Treated with Radiofrequency Ablation.
Oh IS; Sinn DH; Kang TW; Lee MW; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Dig Dis Sci; 2017 Nov; 62(11):3235-3242. PubMed ID: 28983724
[TBL] [Abstract][Full Text] [Related]
7. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; An C; Sun HL; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Int J Hyperthermia; 2019; 36(1):841-853. PubMed ID: 31452408
[No Abstract] [Full Text] [Related]
8. Comparison of Modified Child-pugh (MCP), Albumin-bilirubin (ALBI), and Child-pugh (CP) score for predicting of survival in Hepatocellular Carcinoma Patients Treated with Transcatheter Arterial Chemoembolization.
Liu Y; Cheng C; Zhou H; Hu S; Wang H; Xie Q; Lei L; Wang P; Liu G; Hu H
Bull Cancer; 2021 Oct; 108(10):931-939. PubMed ID: 34247763
[TBL] [Abstract][Full Text] [Related]
9. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
10. Nomogram and Artificial Neural Network for Prognostic Performance on the Albumin-Bilirubin Grade for Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Zhong BY; Ni CF; Ji JS; Yin GW; Chen L; Zhu HD; Guo JH; He SC; Deng G; Zhang Q; Li PC; Yu H; Song JJ; Teng GJ
J Vasc Interv Radiol; 2019 Mar; 30(3):330-338. PubMed ID: 30819473
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization.
Gui B; Weiner AA; Nosher J; Lu SE; Foltz GM; Hasan O; Kim SK; Gendel V; Mani NB; Carpizo DR; Saad NE; Kennedy TJ; Zuckerman DA; Olsen JR; Parikh PJ; Jabbour SK
Am J Clin Oncol; 2018 Sep; 41(9):861-866. PubMed ID: 28418940
[TBL] [Abstract][Full Text] [Related]
12. ALBI and P-ALBI grade in Child-Pugh A patients treated with drug eluting embolic chemoembolization for hepatocellular carcinoma.
Carling U; Røsok B; Line PD; Dorenberg EJ
Acta Radiol; 2019 Jun; 60(6):702-709. PubMed ID: 30205701
[TBL] [Abstract][Full Text] [Related]
13. Proposed New Sub-Grouping for Intermediate-Stage Hepatocellular Carcinoma Using Albumin-Bilirubin Grade.
Hiraoka A; Kumada T; Nouso K; Tsuji K; Itobayashi E; Hirooka M; Kariyama K; Ishikawa T; Tada T; Toyoda H; Kawasaki H; Hiasa Y; Michitaka K
Oncology; 2016; 91(3):153-61. PubMed ID: 27362669
[TBL] [Abstract][Full Text] [Related]
14. An Albumin-Bilirubin (ALBI) Grade-based Prognostic Model For Patients With Hepatocellular Carcinoma Within Milan Criteria.
Ho SY; Liu PH; Hsu CY; Hsia CY; Su CW; Huang YH; Lei HJ; He YJ; Hou MC; Huo TI
Am J Clin Oncol; 2019 Sep; 42(9):698-704. PubMed ID: 31335351
[TBL] [Abstract][Full Text] [Related]
15. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma.
Pinato DJ; Sharma R; Allara E; Yen C; Arizumi T; Kubota K; Bettinger D; Jang JW; Smirne C; Kim YW; Kudo M; Howell J; Ramaswami R; Burlone ME; Guerra V; Thimme R; Ishizuka M; Stebbing J; Pirisi M; Carr BI
J Hepatol; 2017 Feb; 66(2):338-346. PubMed ID: 27677714
[TBL] [Abstract][Full Text] [Related]
16. Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Hiraoka A; Kumada T; Kudo M; Hirooka M; Koizumi Y; Hiasa Y; Tajiri K; Toyoda H; Tada T; Ochi H; Joko K; Shimada N; Deguchi A; Ishikawa T; Imai M; Tsuji K; Michitaka K;
Dig Dis; 2017; 35(6):602-610. PubMed ID: 29040999
[TBL] [Abstract][Full Text] [Related]
17. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
18. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
19. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model.
Kim BK; Shim JH; Kim SU; Park JY; Kim DY; Ahn SH; Kim KM; Lim YS; Han KH; Lee HC
Liver Int; 2016 Jan; 36(1):92-9. PubMed ID: 25950442
[TBL] [Abstract][Full Text] [Related]
20. Survival Analysis Using Albumin-Bilirubin (ALBI) Grade for Patients Treated with Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma.
Young LB; Tabrizian P; Sung J; Biederman D; Bishay VL; Ranade M; Patel RS; Nowakowski FS; Fischman AM; Lookstein RA; Kim E
J Vasc Interv Radiol; 2022 May; 33(5):510-517.e1. PubMed ID: 35150838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
